S&P 500 falls on pressure from retail stocks, weak jobless claims
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) General Counsel Kelley Shannon T. sold a total of 1,324 shares of common stock on August 18, 2025, generating approximately $479,626. The transaction comes as the stock trades near its 52-week high of $393.76, with InvestingPro data showing the company’s market capitalization at $8.74 billion.
The sales were executed in multiple transactions. 458 shares were sold at $358.66, for a total of $164,266. Additionally, 866 shares were sold within a price range of $369.642 to $376.62, resulting in a total value of $315,360.
These sales were disclosed in a Form 4 filing with the Securities and Exchange Commission. Some of the sales were made to cover tax withholding obligations related to the vesting of restricted stock units, while the other sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2024.
Following these transactions, Kelley Shannon T. directly owns 9,173 shares of Madrigal Pharmaceuticals.
In other recent news, Madrigal Pharmaceuticals reported strong second-quarter earnings, with Rezdiffra sales significantly exceeding expectations. The company posted sales of $212.8 million, a 55% increase from the previous quarter, surpassing both Goldman Sachs’ estimates of $150.9 million and FactSet’s consensus of $159.4 million. Madrigal attributed this performance to robust patient demand and increased prescriber penetration. Additionally, Madrigal has secured a global license agreement with CSPC Pharmaceutical (TADAWUL:2070) Group for SYH2086, a preclinical oral GLP-1 receptor agonist, with an upfront payment of $120 million and potential milestone payments up to $2 billion. This transaction is expected to close in the fourth quarter of 2025, pending regulatory clearance. On the analyst front, Goldman Sachs reiterated its Buy rating on Madrigal, maintaining a price target of $567.00, while Jefferies increased its price target to $502.00 following a patent extension for Rezdiffra. Piper Sandler also maintained an Overweight rating with a $400.00 price target, expressing confidence in the ongoing launch of REZDIFFRA. These developments highlight the dynamic landscape surrounding Madrigal Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.